BOSTON, September 20, 2022 /PRNewswire/ — Valo Health, Inc. (“Valo”), the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, has announced that David Berryfounder and CEO of Valo will present at the Virtual Symposium of Private Biotechnology Companies UBS on September 22, 2022 11:30 a.m. EST to 11:55 a.m. EST.
About Valo Health
Valo Health, Inc (“Valo”) is a technology company created to transform the drug discovery and development process using human-centric data and artificial intelligence-based calculations. As a digitally native company, Valo aims to fully integrate human-centric data across the drug development lifecycle into a single unified architecture, accelerating the discovery and development of life-changing drugs. while simultaneously reducing cost, time and failure rates. The company’s Opal computing platform™ is an integrated set of features designed to turn data into valuable insights that can accelerate discovery and enable Valo to advance a strong portfolio of programs in cardiovascular, metabolic, renal, oncology and neurodegenerative diseases. Founded by Flagship Pioneering and based in Boston, MAValo also has offices in Lexington, MA, New York, NY, Branford, Connecticutand San Francisco, California. To learn more, visit www.valohealth.com.
Investors: Graeme BellFinancial director
Media: Jennifer Hanleyvice president of corporate communications
SOURCEValo Health LLC